Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Acceptability of Carraguard (PC-515) as a Vaginal Microbicide
NCT00213031Phase 2Completed
- Sponsor
- Population Council
- Start
- Feb 2000
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in human immunodeficiency virus infection (HIV), Chlamydia trachomatis infection (CT), gonorrhea and 3 more comparing Carraguard with Placebo (2 arms). Primary endpoints: Safety (Toxicity), Compliance and 1 more. Started Feb 2000; status: completed.
02
Drugs
Carraguard
03
Conditions
human immunodeficiency virus infection (HIV)Chlamydia trachomatis infection (CT)gonorrheatrichomoniasis (trich)syphilis
Beyond the preview
Go deeper on NCT00213031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00213031.